
{
  "drug_name": "Cefepime-Enmetazobactam",
  "tradename": "Exblifep",
  "usage_and_dosing": {
    "approved_for": "complicated UTI including pyelonephritis",
    "general_info": [
      "Enmetazobactam is a beta-lactamase inhibitor similar to tazobactam. A key structural difference improves penetration into the bacterial cell. Enmetazobactam protects cefepime from degradation by certain Ambler Class A enzymes, such as ESBLs.",
      "Cefepime-enmetazobactam is not active against bacteria that produce KPC, metallo-beta-lactamase, or OXA enzymes other than OXA-48.",
      "In a recently published phase 3 RCT in patients with complicated UTI or acute pyelonephritis caused by gram-negative bacilli, cefepime-enmetazobactam (compared with piperacillin-tazobactam) met criteria for noninferiority as well as superiority with respect to the primary outcome of clinical cure and microbiologic eradication (JAMA 2022;328:1304).",
      "Good review: Expert Opin Drug Metab Toxicol 2025;21:115."
    ],
    "adult_dose": [
      "Cefepime-enmetazobactam 2.5 gm IV (over 2 hours) q8h.",
      "Product labeling recommends 7 days of treatment, up to 14 days for patient with concurrent bacteremia.",
      "Note that 2.5 gm = cefepime 2 gm + enmetazobactam 0.5 gm.",
      "Reconstitute powder, then immediately dilute in 250 mL of D5W or NS. Complete drug infusion within six hours of dilution."
    ],
    "pediatric_dose": [
      {
        "age": ">28 Days",
        "dose": "Safety and efficacy not established"
      }
    ],
    "renal_adjustment": {
      "CrCl_or_eGFR": [
        "eGFR â‰¥130: 2.5 gm (over 4 hr) q8h",
        "eGFR 60-129: 2.5 gm (over 2 hr) q8h",
        "eGFR 30-59: 1.25 gm (over 2 hr) q8h",
        "eGFR 15-29: 1.25 gm (over 2 hr) q12h",
        "eGFR <15: 1.25 gm, then 0.625 gm (over 2 hr) q24h"
      ],
      "hemodialysis": "1.25 gm, then 0.625 gm (over 2 hr) q24h (dose AD)",
      "CAPD": "2.5 gm q48h"
    },
    "hepatic_adjustment": "No dosage adjustment"
  },
  "adverse_effects": [
    "Hypersensitivity reactions, as with other beta-lactams.",
    "Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain, C. difficile-associated diarrhea.",
    "Increased transaminases, bilirubin.",
    "Headache.",
    "Neurotoxicity (from cefepime): encephalopathy, aphasia, myoclonus, seizures. Typically occurs in patients with renal impairment who did not receive proper dosage adjustment, but has also occurred in patients receiving appropriate dosage.",
    "Positive direct Coombs' test.",
    "Prolonged INR.",
    "Possible false-positive reaction for urine glucose when using some methods (e.g., Clinitest)."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "Cefepime: No evidence of toxicity in humans or animals. Enmetazobactam: No data.",
    "use_during_lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity."
  },
  "antimicrobial_spectrum": {
    "preferred": [
      "Pseudomonas aeruginosa"
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "pharmaceutical_preparations": "Injection",
    "peak_serum_conc_mcg_ml": "Cefepime: 99.8, Enmetazobactam: 19.8 (2.5 gm [over 2 hr] q8h, SS)",
    "protein_binding_percent": "Cefepime: 20, Enmetazobactam: nil",
    "volume_of_distribution_vd": "Cefepime: 20 L (Vss), Enmetazobactam: 25.3 L (Vss)",
    "avg_serum_t1_2_hr": "Cefepime: 2.7, Enmetazobactam: 2.6",
    "elimination": "Cefepime: renal, Enmetazobactam: renal",
    "csf_blood_percent": "Cefepime: 4-34"
  },
  "major_drug_interactions": "No signficant interactions known."
}
